REGENT PACIFIC GROUP LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1075 EUR | +6.97% |
|
+21.38% | -37.19% |
| Sales 2022 | 35K 32.27K 47.69K | Sales 2023 | 291K 268K 397K | Capitalization | 18.13M 16.72M 24.71M |
|---|---|---|---|---|---|
| Net income 2022 | -36M -33.2M -49.05M | Net income 2023 | -25M -23.05M -34.06M | EV / Sales 2022 | 1,045 x |
| Net Debt 2022 | 12.29M 11.33M 16.75M | Net cash position 2023 | 1.22M 1.12M 1.66M | EV / Sales 2023 | 58.1 x |
| P/E ratio 2022 |
-0.67
x | P/E ratio 2023 |
-0.71
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 40.23% |
More Fundamentals
* Assessed data
More news
| 1 day | +6.97% |
Regent Pacific Group Ltd, formerly Endurance RP Ltd is an investment holding company principally engaged in biopharma and investment businesses. The Company operates its business through two segments. The Biopharma segment is engaged in the research, development, manufacture, marketing and sale of pharmaceutical products. The Corporate Investment segment is engaged in the investment in listed and unlisted corporate entities. The Company is also engaged in aging research and developing artificial intelligence (AI) models and tool products related to aging research. It offers aging and longevity clocks to the longevity clinics, preventative medicine organizations, health clubs, insurance companies, and aging research institutions.
Sector
Pharmaceuticals
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- 575 Stock
- RPGA Stock
